| Literature DB >> 33126827 |
Zeeshan Fazal1, Ratnakar Singh1, Fang Fang2, Emmanuel Bikorimana1, Hannah Baldwin1, Andrea Corbet1, Megan Tomlin1, Cliff Yerby1, Nabil Adra3, Costantine Albany3, Sarah Lee4, Sarah J Freemantle1, Kenneth P Nephew2, Brock C Christensen4, Michael J Spinella1,5.
Abstract
Testicular germ cell tumours (TGCTs) respond well to cisplatin-based therapy. However, cisplatin resistance and poor outcomes do occur. It has been suggested that a shift towards DNA hypermethylation mediates cisplatin resistance in TGCT cells, although there is little direct evidence to support this claim. Here we utilized a series of isogenic cisplatin-resistant cell models and observed a strong association between cisplatin resistance in TGCT cells and a net increase in global CpG and non-CpG DNA methylation spanning regulatory, intergenic, genic and repeat elements. Hypermethylated loci were significantly enriched for repressive DNA segments, CTCF and RAD21 sites and lamina associated domains, suggesting that global nuclear reorganization of chromatin structure occurred in resistant cells. Hypomethylated CpG loci were significantly enriched for EZH2 and SUZ12 binding and H3K27me3 sites. Integrative transcriptome and methylome analyses showed a strong negative correlation between gene promoter and CpG island methylation and gene expression in resistant cells and a weaker positive correlation between gene body methylation and gene expression. A bidirectional shift between gene promoter and gene body DNA methylation occurred within multiple genes that was associated with upregulation of polycomb targets and downregulation of tumour suppressor genes. These data support the hypothesis that global remodelling of DNA methylation is a key factor in mediating cisplatin hypersensitivity and chemoresistance of TGCTs and furthers the rationale for hypomethylation therapy for refractory TGCT patients.Entities:
Keywords: Cisplatin; DNA methylation; chemoresistance; testicular germ cell tumour
Mesh:
Substances:
Year: 2020 PMID: 33126827 PMCID: PMC8510620 DOI: 10.1080/15592294.2020.1834926
Source DB: PubMed Journal: Epigenetics ISSN: 1559-2294 Impact factor: 4.528